BMJ1d
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
Background Since the publication of the EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several randomised clinical trials ...
BMJ2d
Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment
Objectives Fatigue is a frequent symptom in rheumatoid arthritis (RA) and has high impact on quality of life. We explored associations between disease activity and fatigue in patients with early RA ...
BMJ1d
Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985–2014
Objectives To examine trends in the incidence of rheumatoid arthritis (RA) from 2005 to 2014 overall and by serological status as compared with 1995–2004 and 1985–1994. Methods We evaluated RA ...
BMJ7d
Psoriatic arthritis: epidemiology, clinical features, course, and outcome
1 University of Toronto, Toronto Western Research Institute, Psoriatic Arthritis Program, University Health Network, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, ...
BMJ3d
Type II collagen facilitates gouty arthritis by regulating MSU crystallisation and inflammatory cell recruitment
Objective Increasing evidence suggests that impaired cartilage is a substantial risk factor for the progression from hyperuricaemia to gout. Since the relationship between cartilage matrix protein and ...
BMJ8d
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
Aims Treating to low disease activity is routine in rheumatoid arthritis, but no comparable goal has been defined for systemic lupus erythematosus (SLE). We sought to define and validate a Lupus Low ...
BMJ12d
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
7 CIRI/Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Fraunhofer Cluster of Excellence for Immune-Mediated Disease (CIMD), Goethe University, Frankfurt, ...
BMJ9d
Baseline predictors of different types of treatment success in rheumatoid arthritis
Objective To perform a comprehensive analysis on predictors of achieving disease activity outcomes by change, response and state measures. Methods We used data from three rheumatoid arthritis (RA) ...
BMJ13d
Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor
Objects Although the association of cigarette smoking (CS) with susceptibility to rheumatoid arthritis (RA) has been established, the impact of CS on anticitrullinated cyclic peptide/protein antibody ...
BMJ13d
Update on D2E7: a fully human anti-tumour necrosis factor α monoclonal antibody
Rheumatoid arthritis (RA) is characterised by persistent joint inflammation and concomitant joint destruction, and in severe cases with extra-articular manifestations, multiple joint involvement, and ...
BMJ13d
Immune cell multiomics analysis reveals contribution of oxidative phosphorylation to B-cell functions and organ damage of lupus
Correspondence to Dr Keishi Fujio, Department of Allergy and Rheumatology, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; fujiok-int{at}h.u-tokyo.ac.jp; Dr Yukiko Iwasaki, Department of Palliative ...